MARKET

KURA

KURA

Kura Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

20.07
-0.89
-4.25%
Closed 16:37 09/20 EDT
OPEN
20.64
PREV CLOSE
20.96
HIGH
20.83
LOW
19.93
VOLUME
558.05K
TURNOVER
--
52 WEEK HIGH
43.00
52 WEEK LOW
15.12
MARKET CAP
1.33B
P/E (TTM)
-10.9213
1D
5D
1M
3M
1Y
5Y
Small biotechs warn Biden, lawmakers on drug price bill impact on R&D
A group of small biotech companies are warning President Biden, Rep. Nancy Pelosi (D-Calif.), Sen. Chuck Schumer (D.-N.Y.) and other top lawmakers about the negative effects a proposed drug pricing
Seekingalpha · 09/08 21:55
Kura Oncology to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D...
GlobeNewswire · 09/07 11:30
Jon Najarian Sees Unusual Options Activity In Lucid Motors, Kura Oncology And More
Jon Najarian spoke on CNBC's "Options Action" about unusually high options activity in Lucid Group Inc (NASDAQ: LCID) on Tuesday.
Benzinga · 08/24 21:05
Suvretta Capital Management, Llc Buys Alphabet Inc, Facebook Inc, Twilio Inc, Sells McDonald's ...
GuruFocus News · 08/24 13:38
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
2 “Strong Buy” Stocks Trading at Rock-Bottom Prices
Buy cheap? Even in the stock market, buyers like to find a bargain. Defining a bargain, however, can be tricky. There’s a stigma that gets attached to low stock prices, based on the reality that most stocks don’t fall without a reason. And those reasons ar...
TipRanks · 08/18 00:07
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 207 companies hit new 52-week lows.
Benzinga · 08/16 14:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KURA. Analyze the recent business situations of Kura Oncology through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KURA stock price target is 44.57 with a high estimate of 53.00 and a low estimate of 38.00.
EPS
Institutional Holdings
Institutions: 224
Institutional Holdings: 70.60M
% Owned: 106.49%
Shares Outstanding: 66.30M
TypeInstitutionsShares
Increased
66
5.17M
New
21
3.45M
Decreased
49
7.67M
Sold Out
20
1.89M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/President/Chief Executive Officer/Director
Troy Wilson
Chief Financial Officer
Marc Grasso
Chief Operating Officer
Kathleen Ford
Other
Stephen Dale
Other
Kirsten Flowers
Other
Bridget Martell
Secretary
James Basta
Lead Director/Independent Director
Faheem Hasnain
Director
Helen Collins
Director
Carol Schafer
Independent Director
Thomas Malley
Independent Director
Diane Parks
Independent Director
Steven Stein
Independent Director
Mary Szela
No Data
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

Webull offers kinds of Kura Oncology Inc stock information, including NASDAQ:KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.